Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRadR2 - A Single Center, Open-label, Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT07828249 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT07828249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07828249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRadR2 - A Single Center, Open-label, Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma
Lead sponsor
Centre Leon Berard
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2029
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma